EX-10.2 4 exhibit102-2020equityinc.htm EX-10.2 exhibit102-2020equityinc
NEUROCRINE BIOSCIENCES, INC. 2020股權激勵計劃於2020年3月16日獲報酬委員會通過,並於2020年5月19日獲股東批准。並由2022年3月14日獲報酬委員會修訂,2022年5月18日獲股東批准。且由2023年3月24日獲報酬委員會修訂,2023年5月17日獲股東批准。再由2024年3月18日獲報酬委員會修訂,2024年5月22日獲股東批准。並由2024年9月13日獲報酬委員會修訂,終止日期為2030年3月15日。 ( 1. 一般。 (a) 繼位並續前計劃。 該計劃是前計劃的繼位並續續。 在生效日期的隔天,(i)將不再在前計劃下授予任何附加獎勵; (ii)前計劃的可用儲備,再加上任何可從時間至時間提供的前計劃的返還股份,將可用於根據本計劃授予的獎勵發行; 及(iii)所有前計劃獎勵將繼續受前計劃條款約束(但任何前計劃的返還股份將可用於根據本計劃授予的獎勵發行)。根據本計劃授予的所有獎勵將受本計劃條款約束。(b) 計劃目的。 公司藉由該計劃旨在擔保並留住員工、董事和顧問的服務,為這些人提供刺激以為公司和任何聯屬公司的成功而盡最大努力,並為這些人提供一個機會以受益於普通股價值的增加,通過授予獎勵。 (c) 可用獎項。 該計劃提供以下獎項的授予:(i)激勵性股票期权; (ii)非統計股票期权; (iii) SARs; (iv)限制性股票獎項; (v) RSU獎項; (vi)表現獎項; 和(vii)其他獎項。(d) 採用日期。 該計劃將於採用日期生效。 在採用日期之前不得根據本計划授予任何獎項。在生效日期之前所授予的任何獎項,若根據適用的稅收、證券和監管規則要求的股東批准迅速收到,並滿足任何其他遵循要求。 (2. 股份受計劃約束。 (a) 股份儲備。根據第2(a)(iii)條款進行的任何調整,根據第2(b)條款進行的任何調整以實施任何資本調整,可以發行的普通股股份總數不得超過以下總和:(i)前計劃的可用儲備;(ii)在2020年年會上批准的額外330萬股;(iii)在2022年年會上批准的額外590萬股;(iv)在2023年年會上批准的額外660萬股;(v)在2024年年會上批准的額外363.5萬股;和(vi)如有的前期計劃返還股份數量 (如有,隨時間提供)。(ii) 根據第2(b)條款,根據本計劃發行的普通股可用於發行的股數將按以下方式進行減少:(A)根據本計劃授予的重估獎項發行的每一股普通股,將減少一股;(B)在2022年5月18日以前根據本計劃授予的每一股普通股,將減少一股;(C)在2022年5月18日後根據本計划授予的每一股普通股,將減少2.13股。 (iii) 根據第2(b)條款,根據本計劃發行的普通股可用於發行的股數將增加( A )根據具體獲利獎項受到的前計劃返還股份或2020年計劃返還股份(在第2(b)(iii)(1) )對重估獎項;(B)在2022年5月18日以前返回到計划的每一股普通股,每一股普通股,將增加一股;(C)根據2022年5月18日後返回到計划的每一股普通股的每一股普通股,將增加2.13股。(b) 股份儲備運作。 (i) 限制適用於根據獎項發行的股份。 為清晰起見,股份儲備是可能根據獎項發行的普通股股份數量限制,並不限制獎項的授予,但公司將隨時保留足夠的普通股股份,以滿足根據此類獎項發行股份的義務。可能會依據駁二資列 (1)、旧約列的契约,为骡子; 3点) 普通股配额不足,予英人。(ii) 行动不构成发行股份并不会减少股份储备。 下列行为不会导致根据计划发行普通股,因此也不会减少受股份储备约束的普通股的数量并可根据计划发行:(1)任何獎項的部分到期或终止而未发行所涵盖的股份;(2)任何獎項支付的粒现金结算;(即,参与者获得现金而不是普通股)。


 
不得低於授予該獎勵之日期的公平市值的100%。儘管如前所述,如果採用或替代其他選擇權或股票增值權,並且符合第409A條和適用時,可以授予具有低於授予該獎項之日期的公平市值100%的行使價格或行使價格的選擇權或SAR 424(a)的法典條款


 
參與者將不具有投票權或其他股東的任何權利,關於 RSU 獎勵,直到實際發行股份以解決已經授予的 RSU 獎勵為止。


 
307473618 v2 13. need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5) the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such person; and (6) the Fair Market Value applicable to an Award. (ii) To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Awards fully effective. (iii) To settle all controversies regarding the Plan and Awards granted under it. (iv) To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. (v) To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock, including any Transaction, for reasons of administrative convenience. (vi) To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair a Participant’s rights under any Award granted while the Plan is in effect unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing. (vii) To amend the Plan in any respect the Board deems necessary or advisable; provided, however, that stockholder approval will be required for any such amendment to the extent required by Applicable Law. Except as provided above, a Participant’s rights under any Award granted before any amendment of the Plan will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing. (viii) To submit any amendment to the Plan for stockholder approval. (ix) To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided, however, that a Participant’s rights under any Award will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing. 307473618 v2 14. (x) Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. (xi) To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant foreign jurisdiction). (c) Delegation to Committee. (i) General. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with any Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated. (ii) Rule 160億3 Compliance. To the extent an Award is intended to qualify for the exemption from Section 16(b) of the Exchange Act that is available under Rule 160億3 of the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more Non-Employee Directors, as determined under Rule 160億3(b)(3) of the Exchange Act, and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. (d) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. (e) Cancellation and Re-Grant of Awards. Except in connection with a Transaction, as provided in Section 6(a) relating to Capitalization Adjustments, or unless the stockholders of the Company have approved such an action within 12 months prior to such an event, neither the Board nor any Committee will have the authority to: (i) reduce the exercise or strike price of any outstanding Option or SAR; or (ii) cancel any outstanding Option or SAR that has an exercise or strike price greater than the then-current Fair Market Value in exchange for cash or other Awards under the Plan. 307473618 v2 15. (f) Delegation to an Officer. The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof; and (ii) determine the number of shares of Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value. 8. TAX WITHHOLDING. (a) Withholding Authorization. As a condition to acceptance of any Award, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for, any sums required to satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company will have no obligation to issue shares of Common Stock subject to an Award, unless and until such withholding obligations are satisfied. (b) Satisfaction of Withholding Obligations. To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; (v) by allowing a Participant to effectuate a “cashless exercise” pursuant to a program developed under Regulation t as promulgated by the Federal Reserve Board; or (vi) by such other method as may be set forth in the Award Agreement. (c) No Obligation to Notify or Minimize Taxes; No Liability to Claims. Except as required by Applicable Law, the Company has no duty or obligation to any Participant to advise such Participant as to the time or manner of exercising an Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such Participant of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to any Participant and will not be liable to any Participant for any adverse tax consequences to such Participant in connection with an Award. As a condition to accepting an Award, each Participant 307473618 v2 16. (i) agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii) acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges that any Option or SAR is exempt from Section 409A only if the exercise or strike price of such Option or SAR is at least equal to the “fair market value” of the Common Stock on the date of grant of such Option or SAR as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR, each Participant agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the exercise or strike price of such Option or SAR is less than the “fair market value” of the Common Stock on the date of grant of such Option or SAR as subsequently determined by the Internal Revenue Service. (d) Withholding Indemnification. As a condition to accepting an Award, in the event that the amount of the Company’s and/or its Affiliate’s withholding obligations in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount. 9. MISCELLANEOUS. (a) Dividends and Dividend Equivalents. Dividends or dividend equivalents may not be paid or credited to any Awards. (b) Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise. (c) Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. (d) Corporate Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by兆.e Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.


 
在獎勵項目滿足條件規定前,沒有參與者被視為持有任何普通股份或具有與之相關權利,且除非:(i)該參與者達到其應滿足的獎勵條件,如適用,並且(ii)反映該獎勵普通股發行在公司紀錄上。


 
涉及交易時,如果參與者在非豁免獎項授予的適用日期是員工或顧問之一。(i)已發生豁免獎項。以下規定適用於任何已發生豁免獎項與交易有關:(1) 如果交易也是第409A條變更控制的一部分,則收購實體不得承擔、續辦或替代已發生豁免獎項。在第409A條變更控制時,已發生豁免獎項的結算將自動加速,股份將立即發行以彰顯已發生的豁免獎項。或者,公司可以決定讓參與者獲得相當於在第409A條變更控制時應發行予參與者的股份公平市值的現金結算。(2)如果交易並非也是第409A條變更控制,那麼收購實體必須承擔、續辦或替代每個已發生的豁免獎項。已發生的豁免獎項的股份將按照若交易未發生時應發放予參與者的進度表由收購實體發放予參與者。依據收購實體的裁量,代替發放股份,收購實體可以決定在每個適用的發放日期代之以等於若交易未發生時股份的公平市值的現金支付,該市值將在交易日期確定。(ii)未發生的豁免獎項。以下規定適用於除非由董事會根據第11(e)條另行決定之外的任何未發生的豁免獎項:(1) 在發生交易時,收購實體將承擔、續辦或替代任何未發生的豁免獎項。除非董事會另行決定,否則任何未發生的豁免獎項將繼續受到交易前適用的授予限制和沒收限制的約束。未發生的豁免獎項的股份將按照若交易未發生時應發放予參與者的進度表由收購實體發放予參與者。根據收購實體的裁量,代替發放股份,收購實體可以在每個適用的發放日期代之以等於若交易未發生時股份的公平市值的現金支付,該市值將在交易日期確定。(2)如果與交易相關時,收購實體不承擔、替代或續辦任何未發生的豁免獎項,那麼此獎項將自動終止並在交易後沒有支付給任何參與者以作為此未發生的豁免獎項被取消之金額。儘管如上,董事會可能依其裁量決定在交易後加速未發生的豁免獎項的授予和結算,或者代之以等於將否則發放予參與者的股份的公平市值的現金支付作為進一步規定在第11(e)(ii)條之後。若董事會未做出相應的選擇,則任何未發生的豁免獎項將在未來交易中在未經支付任何對相關受影響參與者的情況下取消。不論該交易是否也是第409A條變更控制,都將對所有未發生的豁免獎項進行上述處置。(d)非員工董事交易中的非豁免獎項處置。本第11(d)條之以下規定適用並且將取代與交易中非豁免主管獎項的處置有所牴觸的任何條款。(i)如果交易同時是第409A條變更控制的一部分,則收購實體可能不得承擔、續辦或替代非豁免主管獎項。在第409A條變更控制時,任何非豁免主管獎項的授予和結算將自動加速,股份將立即發行以彰顯非豁免主管獎項。或者,公司可以決定讓參與者代之獲得相當於應在第409A條變更控制時發行予參與者的股份的公平市值的現金結算,根據前述條文。(ii)如果交易並非也是第409A條變更控制的一部分,則收購實體必須承擔、續辦或替代非豁免主管獎項。除非董事會另行決定,否則非豁免主管獎項將繼續受到任何交易前適用的授予限制和沒收限制的約束。非豁免主管獎項的股份將按照若交易未發生時應發放予參與者的進度表由收購實體發放予參與者。依據收購實體的裁量,代替發放股份,收購實體可以在每個適用的發放日期代之以等於若交易未發生時股份的公平市值的現金支付,該市值將在交易日期確定。(e)如果RSU獎項是非豁免獎項,則根據此第11(e)條的規定適用並且將取代與此類非豁免獎項的處置有所牴觸的協議或獎項協議:(i)董事會決定提前授予非豁免獎項的授權將不導致對於非豁免獎項相應的股份如期發放日期的加速,除非股份在適用的授予日期前授予對於第409A條的要求是合規的。(ii)公司明確保留權利在符合第409A條的要求並依據財政部法規第1.409A-3(j)(4)(ix)的任何可用豁免的情況下提前結算任何非豁免獎項。(iii)在任何非豁免獎項的條款規定其將根據要求進行結算的交易時事件的範圍內,如果這需要符合第409A條的要求,觸發結算的交易事件還必須構成第409A條變更控制。至於任何非豁免獎項條款規定其將在離職或連續服務終止時進行結算的範圍,如果這需要符合第409A條的要求,觸發結算的終止事件也必須構成離職服務事件。但如果在股份原本將在「離職服務」事件中發放予參與者的時候,該參與者受到適用於代碼第409A條(a)(2)(B)(i)中的「特定雇員」的限制,此職位不予以發放,在參與者離職服務後六個月的日期之前,或如果提前,則發生在此六個月期間內的參與者死亡日期前將不會發放股份。(iv)此第11(e)條中適用於作為非豁免獎項的 RSU 獎項的結算的股份派發將旨在遵守第409A條的要求,以便對參與者發放此類非豁免獎項的股份不會觸發根據第409A條附加的稅負,並且任何此條件模糊之處將得到同樣的解釋。


 
307473618 v2 25. (j) “Capitalization Adjustment” 表示在採納日後發生的與計劃或任何獎勵相關的普通股所做的任何變動或其他事件,並且在該變動或事件中,公司未通過合併、合併、重組、股本重整、重編公司章程、股票股利、非現金財產股利、大額非經常性現金股利、股票分割、股票逆向拆股、清算股息、股份結合、股票交換、公司治理結構變化或任何類似的權益重組交易,而收到公司有任何代價。︰


 
(bb)“《換股法》即1934年修訂版本的證券交易法,和在此之下發布的規則和法規。 (cc)“《換股法》人士”指的是除了公司或任何子公司,任何員工福利計畫或公司或任何子公司的受託人或其他受託人持有公司股票的任何自然人、實體或“集團”(依據《換股法》第13(d)條或第14(d)條的意義),但“《換股法》人士”不包括(i)公司或任何子公司,(ii)公司的員工福利計畫或任何子公司或持有公司員工福利計畫證券的受託人或其他受託人,(iii)臨時持有證券的承銷商,根據這些證券的公開註冊發行,(iv)直接或間接是由公司股東按其對公司股份的比例持有相同比例的實體所有,或(v)任何自然人、實體或在有效日期時是公司證券的業主(不論直接或間接),擁有公司當時已發行證券的合計表決權的50%以上。 (dd)“公允市值”在任何日期指的是,除非董事會另行決定,普通股的價值(依據每股或總體基準,視情況而定)如下確定: (i)如果普通股在任何建立的證券交易所上市或在任何建立的市場上交易,公允市值將是在確定日期報導於其認為可靠的來源的該股的按照該交易所或市場(或普通股交易量最大的交易所或市場)報價的收盤價,報價此股票,當天報價,報告於董事會認為可靠的來源。 (ii)如果在確定日沒有普通股的收盤價,那麼公允市值將是上一次該報價存在的日期的收盤價。 (iii)在缺乏普通股的這種交易所或市場的情況下,或者如果董事會另行決定,公允市值將由董事會按 409A條款和422 以誠實良好信奉的方式決定。 (ee)“完全價值獎”意味著(i)根據以往計劃授予的股票獎或(ii)獎,每種都不是增值獎金。


 
按照普遍認可的會計準則,需要記錄的商譽和無形資產損失;及排除根據接受提交的時間和/或獲得美國食品藥品監督管理局或任何其他規管機構審查和/或批准的影響。此外,董事會保留自行裁定,以確定選擇用於業績期間的績效標準的計算方式,以及在實現任何業績目標後減少或取消應當支付的報酬或經濟利益。部分實現任何業績目標可能導致根據適用授予協議或績效獎項的書面條件,進行與實現程度相對應的支付或兌現。